ChemUhat A brand under Watson

Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B (rHusTNF RII/TNFRSF1B)

ChemWhat Technical Data Sheet (TDS)

Source:Escherichia coli.Molecular Weight:Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids.Quantity:5µg/20µg/1000µgAA Sequence:MPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPTPurity:>97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₃₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Less than 0.1 EU/µg of rHuSTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Quantity: $5\mu g/20\mu g/1000\mu g$ AA Sequence:MPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPTPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF- α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF- α .Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder. Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
AA sequence:MPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPTPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
TVCDSCEDST YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPTPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
GWYCALSKQE GCRLCAPLRK CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS TSPTPurity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Purity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Purity:> 97 % by SDS-PAGE and HPLC analyses.Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Biological Activity:Fully biologically active when compared to standard. The ED ₅₀ as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2 µg/ml, corresponding to a specific activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
activity of > 5000 IU/mg in the presence of 0.25 ng/mL of rHuTNF-α.Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 µm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/µg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.Formulation:Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/μg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Formulation:Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.Endotoxin:Less than 0.1 EU/μg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Endotoxin:Less than 0.1 EU/μg of rHusTNF RII/TNFRSF1B as determined by LAL method.Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a
concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and
stored at \leq -20 $\mathbb C$. Further dilutions should be made in appropriate buffered solutions.
Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature
recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
 12 months from date of receipt, -20 to -70 °C as supplied.
 1 month, 2 to 8 °C under sterile conditions after reconstitution.
 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Usage: ChemWhat Limited in UK offers this branded product for research, development or further
evaluation purposes. NOT FOR HUMAN USE.

Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B

Tumor Necrosis Factor Receptor-I (TNF RI, also known as p55/p60) and TNF RII (also known as p75/p80) are both high affinity receptors for TNF-alpha and -beta, potent mediators of multiple aspects of inflammatory immune responses. Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Whereas all cell types are thought to express TNF RI, TNF RII expression is limited primarily to hematopoietic cells and cells of the immune system. Most of the biological functions of TNF are mediated via TNF RI. Soluble forms of both TNF RI and TNF RII, generated as a result of proteolytic cleavage of the extracellular domains, have been detected in vivo in various biological fluids. The soluble TNF receptors can bind TNF with high affinity and functions as TNF antagonists.

CHEMWHAT LIMITED

Rev. 08/20/2018 V.3

https://www.chemwhat.com

Email: contact@chemwhat.com